3-nitropropionic acid has been researched along with pioglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costa, L; Giovenco, A; Gulino, A; Napolitano, M; Palermo, R; Vacca, A | 1 |
| Ahmed, MAE; El Sayed, NS; El-Sahar, AE; Mansour, RM | 1 |
2 other study(ies) available for 3-nitropropionic acid and pioglitazone
| Article | Year |
|---|---|
Protective effect of pioglitazone, a PPARĪ³ ligand, in a 3 nitropropionic acid model of Huntington's disease.
Topics: Analysis of Variance; Animals; Animals, Newborn; Apoptosis; Cell Survival; Cells, Cultured; Corpus Striatum; Gene Expression Regulation; Histone Deacetylases; Membrane Potential, Mitochondrial; Neurons; Neuroprotective Agents; NF-kappa B; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitro Compounds; Pioglitazone; Propionates; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; RNA, Messenger; Thiazolidinediones | 2011 |
Addressing Peroxisome Proliferator-Activated Receptor-gamma in 3-Nitropropionic Acid-Induced Striatal Neurotoxicity in Rats.
Topics: Animals; Glycogen Synthase Kinase 3 beta; Nitro Compounds; Pioglitazone; PPAR gamma; Propionates; Rats; Telmisartan | 2022 |